Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson's Disease
-
- STATUS
- Not Recruiting
-
- participants needed
- 18
-
- sponsor
- Shanghai East Hospital
Updated on 12 February 2026
Online studies
Summary
This is a single-center, single-arm, dose escalation study, to explore the safety, tolerability and efficacy of human amniotic epithelial stem cells (hAESCs) for idiopathic Parkinson's disease (PD).
Description
hAESCs will be administration through the Ommaya reservoir implanted into the lateral ventricle of subjects with idiopathic PD.
This dose escalation will be followed by an exploratory expansion phase in 3 cohorts.
- Dose A (5×10^7 cells/dose)
- Dose B (1.0×10^8 cells/dose)
- Dose C (1.5×10^8 cells/dose).
Details
| Condition | Idiopathic Parkinson's Disease |
|---|---|
| Age | 40years - 70years |
| Clinical Study Identifier | NCT05691114 |
| Sponsor | Shanghai East Hospital |
| Last Modified on | 12 February 2026 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.